Molecular features of primary and metastatic pancreatic ductal adenocarcinoma (PDAC) may provide clues to treatment response and additional targets for drug development, according to a study presented at the 2018 AACR Pancreatic Cancer: Advances in Science and Clinical Care conference in Boston, Massachusetts.
“Our study characterizes novel molecular features that distinguish highly biologically concordant PDAC primaries and metastases, providing further insight into management,” the authors wrote. Read more . . .